Climb Bio, Inc. CLYM
11.66
(0.23)
(1.93%)
as of 25 Sep
- Market cap
- $682.9M
- P/E
- 0.0×
Follow CLYM
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
18.38 | 15.16 | 27.86 | 31.45 |
Net Debt/EBITDA |
5.65 | 5.11 | 7.08 | 11.66 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.94 | 0.89 | 1.05 | 0.78 | |
Capex/Depreciation |
0.22 | 0.00 | 0.00 | 0.74 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.18) | (0.23) | (0.21) | (0.14) | |
Cash per Share |
1.28 | 1.49 | 1.61 | 2.40 | |
Shareholders Equity per Share |
2.60 | 2.37 | 2.17 | 3.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.60 | 2.37 | 2.17 | 3.15 | |
Free Cash Flow |
(12.25) | (15.63) | (14.38) | (10.81) | |
Working Capital |
86.02 | 98.87 | 109.33 | 180.70 | |
Capital Expenditures |
(0.11) | 0.00 | — | (0.26) | |
Net Current Asset Value |
85.66 | 98.58 | 109.12 | 179.89 | |
| Other line items | |||||
Quick Ratio |
17.56 | 14.47 | 26.91 | 30.86 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.23) | (0.21) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.38 | 1.49 | 0.82 | 1.04 | |
Average Assets |
202.25 | 192.47 | 176.56 | 219.34 | |
Average Common Equity |
197.89 | 186.18 | 170.74 | 212.66 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates